Logo image of 2INV.DE

2INVEST AG (2INV.DE) Stock Fundamental Analysis

FRA:2INV - Deutsche Boerse Ag - DE000A3H3L44 - Common Stock - Currency: EUR

12.6  +0.1 (+0.8%)

Fundamental Rating

4

2INV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. 2INV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 2INV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year 2INV was profitable.
In the past year 2INV has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: 2INV reported negative net income in multiple years.
In multiple years 2INV reported negative operating cash flow during the last 5 years.
2INV.DE Yearly Net Income VS EBIT VS OCF VS FCF2INV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

The Return On Assets of 2INV (26.32%) is better than 95.77% of its industry peers.
The Return On Equity of 2INV (26.70%) is better than 92.96% of its industry peers.
With an excellent Return On Invested Capital value of 21.31%, 2INV belongs to the best of the industry, outperforming 98.59% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 2INV is in line with the industry average of 13.59%.
The 3 year average ROIC (11.84%) for 2INV is below the current ROIC(21.31%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 26.32%
ROE 26.7%
ROIC 21.31%
ROA(3y)-1.72%
ROA(5y)11.4%
ROE(3y)-1.65%
ROE(5y)11.58%
ROIC(3y)11.84%
ROIC(5y)16.55%
2INV.DE Yearly ROA, ROE, ROIC2INV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 2INV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2INV.DE Yearly Profit, Operating, Gross Margins2INV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K 40K 60K 80K

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, 2INV has less shares outstanding
The number of shares outstanding for 2INV has been reduced compared to 5 years ago.
2INV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2INV.DE Yearly Shares Outstanding2INV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
2INV.DE Yearly Total Debt VS Total Assets2INV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 32.62 indicates that 2INV is not in any danger for bankruptcy at the moment.
2INV's Altman-Z score of 32.62 is amongst the best of the industry. 2INV outperforms 100.00% of its industry peers.
There is no outstanding debt for 2INV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.62
ROIC/WACCN/A
WACCN/A
2INV.DE Yearly LT Debt VS Equity VS FCF2INV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

2INV has a Current Ratio of 71.64. This indicates that 2INV is financially healthy and has no problem in meeting its short term obligations.
2INV has a better Current ratio (71.64) than 100.00% of its industry peers.
A Quick Ratio of 71.64 indicates that 2INV has no problem at all paying its short term obligations.
2INV has a Quick ratio of 71.64. This is amongst the best in the industry. 2INV outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 71.64
Quick Ratio 71.64
2INV.DE Yearly Current Assets VS Current Liabilites2INV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

2INV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1304.88%, which is quite impressive.
EPS 1Y (TTM)1304.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
2INV.DE Yearly Revenue VS Estimates2INV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 5M 10M 15M
2INV.DE Yearly EPS VS Estimates2INV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 -0.5 -1 -1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 3.26, which indicates a rather cheap valuation of 2INV.
Based on the Price/Earnings ratio, 2INV is valued cheaper than 98.59% of the companies in the same industry.
2INV is valuated cheaply when we compare the Price/Earnings ratio to 24.21, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 3.26
Fwd PE N/A
2INV.DE Price Earnings VS Forward Price Earnings2INV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
2INV.DE Per share data2INV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 2INV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

2INVEST AG

FRA:2INV (5/9/2025, 7:00:00 PM)

12.6

+0.1 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-02 2025-04-02
Earnings (Next)08-04 2025-08-04
Inst Owners0.27%
Inst Owner ChangeN/A
Ins Owners82.9%
Ins Owner ChangeN/A
Market Cap72.45M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 3.26
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)3.86
EY30.63%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.42
FCFYN/A
OCF(TTM)-4.42
OCFYN/A
SpS0
BVpS14.43
TBVpS14.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 26.32%
ROE 26.7%
ROCE 30.27%
ROIC 21.31%
ROICexc 33.87%
ROICexgc 33.87%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.72%
ROA(5y)11.4%
ROE(3y)-1.65%
ROE(5y)11.58%
ROIC(3y)11.84%
ROIC(5y)16.55%
ROICexc(3y)17.54%
ROICexc(5y)53.02%
ROICexgc(3y)17.54%
ROICexgc(5y)53.04%
ROCE(3y)16.81%
ROCE(5y)23.52%
ROICexcg growth 3Y188.36%
ROICexcg growth 5YN/A
ROICexc growth 3Y188.36%
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 2816.22
Cash Conversion N/A
Profit Quality N/A
Current Ratio 71.64
Quick Ratio 71.64
Altman-Z 32.62
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1304.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y157.14%
EBIT growth 3Y216.03%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-393.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-393.32%
OCF growth 3YN/A
OCF growth 5YN/A